delamanid

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
0204020112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The European Respiratory Journal has recently discussed delamanid and bedaquiline and their use in difficult-to-treat cases… (More)
  • table 1
Is this relevant?
2016
2016
There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
BACKGROUND The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB… (More)
  • table 1
  • table 2
  • table 3
  • table 3
  • table 4
Is this relevant?
2015
2015
Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to… (More)
Is this relevant?
2015
2015
1 Laveneziana P, Garcia G, Joureau B, et al. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial… (More)
  • table 1
Is this relevant?
2014
2014
Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co… (More)
Is this relevant?
2014
2014
Delamanid is a new drug for the treatment of multidrug-resistant tuberculosis. Individuals who are co-infected with human… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2011
2011
BACKGROUND Delamanid (OPC-67683) is a novel mycolic acid biosynthesis inhibitor active against Mycobacterium tuberculosis at a… (More)
Is this relevant?